[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"personalized-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:personalized-medicine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,86,116,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100593686","fluid-management-and-individualized-resuscitation-in-sepsis-100593686",false,"NCT07009665","Fluid Management and Individualized Resuscitation in Sepsis","FLUIDS","Inclusion Criteria:\n\n* Adult patients (≥ 18 years of age);\n* Referred to internal medicine, nephrology, geriatric medicine, oncology, hematology, lung medicine, rheumatology, gastrointestinal \u002F liver medicine, urology, or emergency medicine (non-trauma);\n* Confirmed or suspected infection according to the physician's judgement upon arrival to the ED, based the presence of an acute phase response not due to an alternative non-infectious cause (i.e., body temperature \\\u003C 36°C or \\>38°C, leukocyte count \\> 12 x109\u002FL or C-reactive protein \\> 50 mg\u002FL), and\u002For on symptoms suggestive for an infection (e.g. productive cough, dyspnea, dysuria, pollakisuria, abdominal pain, erythema)\n* Need for hemodynamic resuscitation, based on any of the following (first measurement at ED arrival \\[triage\\]):\n* Mean arterial pressure (MAP) \\\u003C 70 mmHg\n* Systolic blood pressure (SBP) \\\u003C 90 mmHg or a SBP decrease \\>40 mmHg\n* Lactate \\> 4.0 mmol\u002FL\n* Shock index\\* \\> 0.9\n* Enrolled in study within one hour after ED arrival\n\nExclusion Criteria:\n\n* Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, drug overdose, or injury from burn or trauma, diabetic ketoacidosis, hyper-osmolarity syndrome, pancreatitis\n* Known aortic insufficiency, aortic abnormalities, or intraventricular heart defect, such as ventral septal defect or atrial septal defect\n* Known advanced heart failure - meaning NYHA IV functional class HF, on waiting list for heart transplant, LVAD recipient or chronic inotrope use.\n* Known end-stage kidney disease (dialysis-dependent CKD stage 5 or eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²)\n* Decompensated liver cirrhosis at ED admission (e.g., ascites, hepatic encephalopathy, or variceal bleeding)\n* Hemodynamic instability due to active bleeding\n* Patient has received \\>1 liter of IV fluid prior to study randomization\n* Requires immediate surgery\n* Transfer from another hospital after initiation of therapy (a.o. referred by another hospital ICU) or another in-hospital setting\n* Pregnant women\n* Trauma patients\n* Suspected intra-abdominal hypertension, based on the presence of portal hypertension (i.e. presence of ascites due to liver cirrhosis, esophageal varices or as measured by Doppler ultrasound)\n* Inability to obtain IV access\n* Patient uncouples from treatment algorithm\n* Patient should be excluded based on the opinion of the Clinician\u002FInvestigator\n* Not able to commence treatment protocol within 1 hour after randomization\n* Potential ICU-admission unwanted by advanced care directive (e.g., limited life expectancy)","ALL","18 Years",{"count":19,"type":20},188,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to find out if a personalized treatment approach can improve care for people with sepsis in the emergency department (ED).\n\nSepsis is a life-threatening condition that happens when the body has an uncontrolled response to an infection. This can lead to low blood pressure, organ failure, and death if not treated quickly. Right now, most people with sepsis receive a standard amount of fluids to raise their blood pressure. But this one-size-fits-all approach can lead to fluid overload and other complications. Because each person responds differently, this study will test whether a more personalized treatment-based on how the heart responds to fluids-can lead to safer and more effective care.\n\nThe study will include 188 adults who come to the ED at the University Medical Centre Groningen (UMCG) with suspected sepsis in need of hemodynamic resuscitation. Everyone in the study will receive fluids to support their blood pressure.\n\nParticipants will be randomly assigned to one of two groups:\n\n* Personalized treatment group: Fluids and vasopressors (medications that raise blood pressure) will be given based on how the heart responds to each fluid dose. This response is measured using a non-invasive monitor that tracks stroke volume index (ΔSVI)-a measure of how much blood the heart pumps.\n* Standard care group: Fluids will be given based on current guidelines (30 milliliters per kilogram of body weight), as decided by the treating doctor.\n\nResearchers will compare how much fluid is given during the first 3 hours of care. They will also look at:\n\n* When and how much vasopressor medicine is used\n* How well blood pressure and circulation respond\n* Signs of organ recovery or damage\n* How long participants stay in the hospital\n* Any problems or side effects during treatment\n\nThe researchers hope that this personalized approach will lead to using less fluid, starting vasopressors earlier, and helping people with sepsis recover more safely and quickly.",[26,27,28,29,30,31],"Sepsis","Shock","Personalized Medicine","Emergency Medicine","Critical Care, Fluid Resuscitation","Fluid Responsiveness",[26,27,33,34,35,36,37],"Personalized medicine","emergency medicine","critical care","fluid resuscitation","fluid responsiveness","RECRUITING","2025-12-14",{"date":41,"type":42},"2025-12-19","ACTUAL",{"date":44,"type":42},"2025-09-01",{"date":46,"type":20},"2026-12-01",{"name":48,"class":49},"University Medical Center Groningen","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":50},"100609844","evaluating-a-clinical-decision-support-tool-for-antiretroviral-therapy-optimization-100609844","NCT07219862","Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization","Inclusion Criteria:\n\nHIV patients\n\n1. Documented HIV-1 infection\n2. Greater than 18 years of age\n3. Genotype resistance testing previously conducted or scheduled through clinical care\n\nProviders:\n\nHIV care providers who will determine treatment selections, with or without utilizing our clinical decision support tool\n\nExclusion Criteria:\n\nHIV patients:\n\n1\\. Refusal or inability to give informed consent\n\nProviders:\n\n1\\. Refusal to give informed consent",true,{"count":59,"type":20},250,[23],"This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging.\n\nIn this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care.\n\nThe investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.",[63,64,65,66,67,28,68],"HIV (Human Immunodeficiency Virus)","Clinical Decision Support System (CDSS)","Antiretroviral Therapy, Highly Active","INDIVIDUALIZED THERAPY","AIDS (Acquired Immune Deficiency Syndrome)","Precision Medicine",[70,71,72,73,74,75],"hiv","clinical decision support system","antiretroviral therapy","aids","personalized medicine","precision medicine","NOT_YET_RECRUITING","2025-10-20",{"date":79,"type":42},"2025-10-22",{"date":81,"type":20},"2028-09-01",{"date":83,"type":20},"2031-09-01",{"name":85,"class":49},"Keck School of Medicine of USC",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":5},"100432937","a-multicenter-study-for-evaluating-a-digital-support-system-in-childhood-obesity-treatment-100432937","NCT04917601","A Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment","A Randomized Controlled Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment (EurEvira)","EurEvira","Inclusion Criteria:\n\n* Age \\>4.0 and \\\u003C17.0 years of age at inclusion\n* Obesity defined based on the International Obesity Task Force criteria iso-BMI 30 - 40 kg\u002Fm2\n* Willingness to participate in an obesity treatment clinical trial\n* Family ability to communicate in the language of the country of residence e.g. write and read messages in the mobile application\n* Parents having a smart phone and an email address\n\nExclusion Criteria:\n\n* Morbid obesity defined as iso-BMI\\>40kg\u002Fm2 independently of age\n* Endocrine disorders other than well controlled hypothyroidism\n* Metabolic disorders of importance for weight control - to be discussed\n* Treatment for depression and other psychiatric disorders during the last 6 months before inclusion\n* Pharmacological treatment of importance for weight control\n* Hypothalamic or monogenic obesity, e.g. syndromes and Mb Down\n* Severe neuropsychiatric disorders that could affect study compliance\n* Eating disorders requiring therapy during the last six months before inclusion or observed at the inclusion screening.","4 Years","17 Years",{"count":97,"type":20},680,[23],"Evira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians can easily follow the child's weight development. The purpose of this randomized controlled study is to evaluate the effect of adding Evira to the already locally used life-style treatment of childhood obesity.",[101,102,103,28],"Childhood Obesity","Adolescent Obesity","mHealth",[105,106],"Obesity treatment","Digital support system","2025-09-30",{"date":109,"type":42},"2025-10-06",{"date":111,"type":42},"2022-05-24",{"date":113,"type":20},"2027-12",{"name":115,"class":49},"Karolinska Institutet",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":50},"100580801","feasibility-trial-of-darwin-oncotreat-and-oncotarget-precision-medicine-testing-100580801","NCT06842030","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients With Limited Metastatic Disease That Failed First-Line Systemic Therapy","Inclusion Criteria:\n\n* Patients age ≥18 years with metastatic solid tumor who are candidates for comprehensive involved site radiotherapy to all areas of disease seen on whole body imaging.\n* Patients with brain metastases are eligible provided they qualify as oligometastases (up to 10 lesions based on the SABR-COMET-10 trial) and are treatable with radiotherapy to all areas of visible disease.\n* Patients with adequate bone marrow (absolute neutrophil ≥1000, hemoglobin ≥ 9 g\u002Fdl, platelets ≥100,000), kidney (creatinine ≤1.5 times upper limit of normal) and liver (bilirubin ≤1.5 times upper limit of normal).\n* Patients being treated by radiation oncology at Good Samaritan University Hospital.\n\nExclusion Criteria:\n\n* Patients with an estimated median survival of less than 6 months using the published and validated NEAT methodology.\n* Patients who are pregnant and\u002For breast feeding or those with severe uncontrolled cardiac, pulmonary, infectious or organic brain disease.",{"count":124,"type":20},20,[23],"This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology. Eligible oligometastatic patients that are receiving radiation therapy (n=20) will undergo mandatory tumor biopsy prior to precision medicine testing. Formalin fixed paraffin embedded tissue with \\>50% tumor will be sent to the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center for Darwin OncoTarget and OncoTreat testing. This will be supplementing routine clinical care with the goal of improving outcomes. The treating oncologist will decide to administer standard of care systemic therapy or proceed with treatment recommended by precision medicine testing. Feasibility outcomes include the ability to have the OncoTarget and OncoTreat test performed based on tumor type and pathology, ability to procure agents, change in medication use, and identification of unknown barriers. This study is assessing the use of precision medicine in a population has documented poor outcomes with implications aimed at improving these outcomes.",[28,128,129],"Oligometastatic Disease","Feasibility","2025-02-18",{"date":132,"type":42},"2025-02-24",{"date":134,"type":20},"2025-03-10",{"date":136,"type":20},"2027-04-10",{"name":138,"class":49},"Good Samaritan Hospital Medical Center, New York",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":50},"100571877","personalized-treatment-of-refractory-bppv-100571877","NCT06725966","Personalized Treatment of Refractory BPPV","Personalized Medicine to Treat Refractory Benign Paroxysmal Positional Vertigo, Through Computational Fluid Dynamics Analysis From Magnetic Resonance Image Reconstructions","Inclusion Criteria:\n\n* A. Diagnosed with BPPVp according to the Barany Society criteria:\n\n  1. Recurrent episodes of vertigo or positional instability, triggered by lying down or turning the head in the supine position.\n  2. Episodes lasting less than 1 minute.\n  3. Positional nystagmus observed after a latency period during the Dix-Hallpike test (DHT), with an upward vertical component and a torsional component (clockwise on the left side and counterclockwise on the right).\n  4. Symptoms not explained by any other cause.\n\n     AND\n* B. Refractory to otolith repositioning maneuvers (Epley and\u002For Semont maneuvers), with persistence of symptoms after three attempts.\n\nExclusion Criteria:\n\n* Cognitive impairment that prevents understanding of their condition and the required procedures.\n* Pathological conditions that hinder the execution of the maneuvers.\n* BPPV involving canals other than the posterior canal or bilateral posterior canal involvement.\n* Low educational level, which may impede understanding of the procedures and informed consent.","100 Years",{"count":148,"type":20},54,[23],"Background: Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo, often effectively treated with standard canalith repositioning maneuvers (CRMs). However, approximately 12.5% of cases remain refractory, leading to persistent symptoms and increased healthcare burden. Variations in the anatomical orientation of the semicircular canals (SCCs) may explain the resistance to conventional maneuvers. This study explores a personalized medicine approach, utilizing computational fluid dynamics (CFD) based on MRI reconstructions to tailor CRMs with the help of mechanical rotation chair according to individual inner ear anatomy.\n\nMethods: The investigators conducted a randomized, multicenter, open-label study targeting patients with refractory posterior canal BPPV. Participants were allocated to either a control group (receiving repeated standard CRMs and Brandt-Daroff exercises) or an intervention group (receiving personalized CRMs based on CFD simulations derived from MRI scans). The intervention group's maneuvers were executed using a mechanical rotational chair designed for precise angulation. Primary outcomes included resolution of nystagmus and vertigo symptoms, while secondary outcomes measured the reduction in healthcare visits and improved quality of life (Dizziness Handicap Inventory score).",[152,28],"Benign Paroxysmal Positional Vertigo",[154,155,156,157,158,159],"BPPV","Benign paroxysmal positional vertigo","Computational fluid dynamics","MRI","Canalith repositioning maneuvers","Mechanical rotation chair","2024-12-08",{"date":162,"type":42},"2024-12-10",{"date":164,"type":42},"2024-07-01",{"date":166,"type":20},"2026-12-31",{"name":168,"class":49},"Hospital Clinico Universitario de Santiago"]